ATE487474T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents
Verbindungen zur behandlung von stoffwechselstörungenInfo
- Publication number
- ATE487474T1 ATE487474T1 AT04759257T AT04759257T ATE487474T1 AT E487474 T1 ATE487474 T1 AT E487474T1 AT 04759257 T AT04759257 T AT 04759257T AT 04759257 T AT04759257 T AT 04759257T AT E487474 T1 ATE487474 T1 AT E487474T1
- Authority
- AT
- Austria
- Prior art keywords
- carbon atoms
- ring
- alkyl
- hydrogen
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 perfluoromethoxy Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46296003P | 2003-04-15 | 2003-04-15 | |
| PCT/US2004/010799 WO2004091486A2 (en) | 2003-04-15 | 2004-04-08 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE487474T1 true ATE487474T1 (de) | 2010-11-15 |
Family
ID=33300020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04759257T ATE487474T1 (de) | 2003-04-15 | 2004-04-08 | Verbindungen zur behandlung von stoffwechselstörungen |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7514555B2 (de) |
| EP (1) | EP1633340B1 (de) |
| JP (2) | JP4766693B2 (de) |
| KR (1) | KR101127390B1 (de) |
| CN (2) | CN101912380A (de) |
| AT (1) | ATE487474T1 (de) |
| AU (1) | AU2004229418B2 (de) |
| BR (1) | BRPI0409469B1 (de) |
| CA (1) | CA2521621C (de) |
| CY (1) | CY1111310T1 (de) |
| DE (1) | DE602004030004D1 (de) |
| DK (1) | DK1633340T3 (de) |
| ES (1) | ES2353601T3 (de) |
| IL (1) | IL171269A (de) |
| MX (1) | MXPA05011042A (de) |
| NO (1) | NO20054791L (de) |
| NZ (1) | NZ542739A (de) |
| PL (1) | PL1633340T3 (de) |
| PT (1) | PT1633340E (de) |
| RU (1) | RU2358722C2 (de) |
| SI (1) | SI1633340T1 (de) |
| UA (1) | UA80195C2 (de) |
| WO (1) | WO2004091486A2 (de) |
| ZA (1) | ZA200507704B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101059776B1 (ko) | 2001-06-12 | 2011-08-26 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| AU2003286728A1 (en) * | 2002-11-01 | 2004-06-07 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| RU2005128501A (ru) * | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
| MXPA05011042A (es) | 2003-04-15 | 2005-12-15 | Wellstat Therapeutics Corp | Compuestos para el tratamieno de trastornos metabolicos. |
| WO2004093806A2 (en) | 2003-04-22 | 2004-11-04 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN100348186C (zh) * | 2003-04-30 | 2007-11-14 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| BRPI0413758A (pt) * | 2003-08-20 | 2006-10-31 | Wellstat Therapeutics Corp | compostos para o tratamento de transtornos metabólicos |
| US8022249B2 (en) * | 2005-04-01 | 2011-09-20 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| JP2009528275A (ja) * | 2006-01-25 | 2009-08-06 | ウェルスタット セラピューティクス コーポレイション | 代謝障害を処置するための化合物 |
| US7915429B2 (en) * | 2006-01-25 | 2011-03-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009525982A (ja) * | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| EP1983972A4 (de) * | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| CN101394738A (zh) * | 2006-02-28 | 2009-03-25 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2647258A1 (en) | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
| CN101437506A (zh) * | 2006-05-18 | 2009-05-20 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CN101466266A (zh) * | 2006-06-09 | 2009-06-24 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| AU2007285827A1 (en) | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
| US8481595B2 (en) * | 2008-01-15 | 2013-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| AU2009258040B8 (en) | 2008-03-13 | 2014-04-24 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| US8664433B2 (en) * | 2008-05-05 | 2014-03-04 | Wellstat Therapeutics Corporation | Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid |
| EP2365746B1 (de) | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthese von (phenylalkyloxy)phenyloxobutansäuren |
| JP6458784B2 (ja) * | 2016-08-03 | 2019-01-30 | 横河電機株式会社 | 駆動回路および電磁流量計 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3048633A (en) * | 1960-12-02 | 1962-08-07 | American Home Prod | N-lower alkyl-2-(benzyloxatedphenyl)-glycolamide |
| GB1482195A (en) * | 1973-08-23 | 1977-08-10 | Beecham Group Ltd | Biologically active phenyl(thio)ether derivatives |
| JPS57150633A (en) | 1981-03-14 | 1982-09-17 | Nissan Chem Ind Ltd | 4-benzyloxymandelic acid and its preparation |
| DK171627B1 (da) * | 1983-01-31 | 1997-03-03 | Lilly Co Eli | Anvendelse af beta-phenethanolamin og farmaceutiskacceptable salte deraf samt dyrefoderpræblanding med indhold deraf |
| JPS6261587A (ja) | 1985-09-12 | 1987-03-18 | Ajinomoto Co Inc | 光学活性（ｒ）−ヒドロキシマンデル酸エステル中間体の製造法 |
| DE3621775A1 (de) * | 1986-03-13 | 1988-01-07 | Thomae Gmbh Dr K | Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB8806471D0 (en) * | 1988-03-18 | 1988-04-20 | Tisdale M J | Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours |
| NZ231735A (en) * | 1988-12-23 | 1992-04-28 | Ici Plc | Alcohol/ether derivatives, preparation and pharmaceutical compositions thereof |
| JP3135936B2 (ja) | 1991-06-10 | 2001-02-19 | 日新製鋼株式会社 | アルミニウム含有ステンレス鋼のアルミニウム調整方法 |
| AU3351293A (en) | 1992-01-21 | 1993-08-03 | Glaxo Group Limited | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5665387A (en) * | 1994-09-01 | 1997-09-09 | K.U. Leuven Research & Development | Methods and compositions for primary and secondary prevention of autoimmune diabetes |
| FR2752422B1 (fr) * | 1996-08-16 | 1998-11-06 | Lipha | Composition pharmaceutique contenant des acides 4-oxo-butanoiques |
| KR20010042298A (ko) | 1998-03-31 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논 |
| EP1085846A2 (de) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Mehrfachbindende inhibitoren des microsomalen triglyceridtransferase-proteins |
| DE19830770C1 (de) * | 1998-07-09 | 2000-05-18 | Sueddeutsche Kalkstickstoff | Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung |
| KR101059776B1 (ko) * | 2001-06-12 | 2011-08-26 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| JP4825375B2 (ja) | 2001-08-28 | 2011-11-30 | 株式会社 資生堂 | ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤 |
| AU2003286728A1 (en) | 2002-11-01 | 2004-06-07 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| RU2005128501A (ru) * | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
| MXPA05011042A (es) | 2003-04-15 | 2005-12-15 | Wellstat Therapeutics Corp | Compuestos para el tratamieno de trastornos metabolicos. |
| WO2004093806A2 (en) * | 2003-04-22 | 2004-11-04 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN100348186C (zh) * | 2003-04-30 | 2007-11-14 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| BRPI0413758A (pt) * | 2003-08-20 | 2006-10-31 | Wellstat Therapeutics Corp | compostos para o tratamento de transtornos metabólicos |
| US7163470B2 (en) | 2004-06-25 | 2007-01-16 | Callaway Golf Company | Golf club head |
| US8022249B2 (en) | 2005-04-01 | 2011-09-20 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009528275A (ja) * | 2006-01-25 | 2009-08-06 | ウェルスタット セラピューティクス コーポレイション | 代謝障害を処置するための化合物 |
| WO2007087505A2 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
-
2004
- 2004-04-08 MX MXPA05011042A patent/MXPA05011042A/es active IP Right Grant
- 2004-04-08 BR BRPI0409469A patent/BRPI0409469B1/pt not_active IP Right Cessation
- 2004-04-08 WO PCT/US2004/010799 patent/WO2004091486A2/en not_active Ceased
- 2004-04-08 DE DE602004030004T patent/DE602004030004D1/de not_active Expired - Lifetime
- 2004-04-08 JP JP2006509802A patent/JP4766693B2/ja not_active Expired - Fee Related
- 2004-04-08 PT PT04759257T patent/PT1633340E/pt unknown
- 2004-04-08 SI SI200431588T patent/SI1633340T1/sl unknown
- 2004-04-08 RU RU2005135441/15A patent/RU2358722C2/ru not_active IP Right Cessation
- 2004-04-08 CN CN2010102296172A patent/CN101912380A/zh active Pending
- 2004-04-08 CA CA2521621A patent/CA2521621C/en not_active Expired - Fee Related
- 2004-04-08 DK DK04759257.1T patent/DK1633340T3/da active
- 2004-04-08 US US10/531,618 patent/US7514555B2/en not_active Expired - Lifetime
- 2004-04-08 CN CNA200480010105XA patent/CN1774244A/zh active Pending
- 2004-04-08 AU AU2004229418A patent/AU2004229418B2/en not_active Ceased
- 2004-04-08 ES ES04759257T patent/ES2353601T3/es not_active Expired - Lifetime
- 2004-04-08 PL PL04759257T patent/PL1633340T3/pl unknown
- 2004-04-08 AT AT04759257T patent/ATE487474T1/de active
- 2004-04-08 EP EP04759257A patent/EP1633340B1/de not_active Expired - Lifetime
- 2004-04-08 KR KR1020057019565A patent/KR101127390B1/ko not_active Expired - Fee Related
- 2004-04-08 NZ NZ542739A patent/NZ542739A/en not_active IP Right Cessation
- 2004-08-04 UA UAA200510355A patent/UA80195C2/uk unknown
-
2005
- 2005-09-23 ZA ZA200507704A patent/ZA200507704B/en unknown
- 2005-10-02 IL IL171269A patent/IL171269A/en not_active IP Right Cessation
- 2005-10-18 NO NO20054791A patent/NO20054791L/no not_active Application Discontinuation
-
2009
- 2009-02-25 US US12/392,675 patent/US7973052B2/en not_active Expired - Fee Related
-
2011
- 2011-02-09 CY CY20111100157T patent/CY1111310T1/el unknown
- 2011-05-13 JP JP2011108809A patent/JP5371062B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007087505A3 (en) | Compounds for the treatment of metabolic disorders | |
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007137008A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007095462A3 (en) | Compounds for the treatment of metabolic disorders | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| NO20003399D0 (no) | <Alfa>-amionoamidderivater som er nyttige som smertestillende midler | |
| UA88772C2 (ru) | Соединения для лечения расстройств метаболизма | |
| ATE540675T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2007087504A3 (en) | Compounds for the treatment of metabolic disorders | |
| WO2007092729A3 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1633340 Country of ref document: EP |